WO2005079419A3 - Methods of treating immunopathological disorders - Google Patents

Methods of treating immunopathological disorders Download PDF

Info

Publication number
WO2005079419A3
WO2005079419A3 PCT/US2005/004895 US2005004895W WO2005079419A3 WO 2005079419 A3 WO2005079419 A3 WO 2005079419A3 US 2005004895 W US2005004895 W US 2005004895W WO 2005079419 A3 WO2005079419 A3 WO 2005079419A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
methods
component
disorders
tlr2
Prior art date
Application number
PCT/US2005/004895
Other languages
French (fr)
Other versions
WO2005079419A2 (en
Inventor
Eyal Raz
Vanessa Doreen Redecke
Anthony A Horner
Original Assignee
Univ California
Eyal Raz
Vanessa Doreen Redecke
Anthony A Horner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Eyal Raz, Vanessa Doreen Redecke, Anthony A Horner filed Critical Univ California
Publication of WO2005079419A2 publication Critical patent/WO2005079419A2/en
Publication of WO2005079419A3 publication Critical patent/WO2005079419A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides methods of treating immunopathological disorders having a Th1 component, e.g., autoimmune disorders and allograft rejection, and/or an M1 macrophage component, e.g., an M1-mediated inflammatory disorder. The methods generally involve administering to an individual in need thereof an effective amount of a toll-like receptor-2 (TLR2) agonist. The present invention provides combination therapies for treating an immunopathology having a Th1 and/or an M1 macrophage component, generally involving administering a TLR2 agonist and at least one additional therapeutic agent.
PCT/US2005/004895 2004-02-17 2005-02-16 Methods of treating immunopathological disorders WO2005079419A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54535304P 2004-02-17 2004-02-17
US60/545,353 2004-02-17

Publications (2)

Publication Number Publication Date
WO2005079419A2 WO2005079419A2 (en) 2005-09-01
WO2005079419A3 true WO2005079419A3 (en) 2006-07-06

Family

ID=34886139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004895 WO2005079419A2 (en) 2004-02-17 2005-02-16 Methods of treating immunopathological disorders

Country Status (1)

Country Link
WO (1) WO2005079419A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753687A (en) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US20090099191A1 (en) * 2006-02-02 2009-04-16 Gudkov Andrei V Inhibition of nf-kb
EP2170392A2 (en) 2007-06-28 2010-04-07 Opsona Therapeutics Limited Composition and method for treatment of autoimmune disease
WO2009004094A2 (en) * 2007-07-05 2009-01-08 Opsona Therapeutics Limited Compounds and methods for the treatment of renal disease
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
PL2618842T3 (en) 2010-09-22 2019-10-31 Ena Therapeutics Pty Ltd Novel immunostimulatory method
AU2018241248A1 (en) * 2017-03-31 2019-09-05 Ena Respiratory Pty Ltd Treatment of respiratory infection with a TLR2 agonist

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells
US6376528B1 (en) * 1996-02-13 2002-04-23 G. D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20040259790A1 (en) * 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
US6376528B1 (en) * 1996-02-13 2002-04-23 G. D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20040259790A1 (en) * 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALIPRANTIS A.O. ET AL: "Cell Activation and Apoptosis by Bacterial Lipoproteins Through Toll-like Receptor-2", SCIENCE, vol. 285, 30 July 1999 (1999-07-30), pages 736 - 739, XP000985942 *

Also Published As

Publication number Publication date
WO2005079419A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
WO2005079419A3 (en) Methods of treating immunopathological disorders
WO2006070286A3 (en) Monoclonal antibodies against nkg2a
WO2006066088A3 (en) Methods for treating autoimmune disorders
WO2005117972A3 (en) Preventing autoimmune disease by using an anti-cd20 antibody
EP1945322A4 (en) Systems and methods for administering an exercise program
WO2006077471A3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
WO2006037016A3 (en) Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
WO2006068987A3 (en) Uses of il-23 antagonists in the treatment of diabetes mellitus
EP1751271A4 (en) Methods and compositions for the dietary management of autoimmune disorders
WO2006009698A3 (en) Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior
WO2008002933A3 (en) Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2010011466A3 (en) Controlled-release cns modulating compositions and methods for the treatment of otic disorders
WO2010014784A3 (en) Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2007067863A3 (en) Session continuity in multimedia services
WO2005115453A3 (en) Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
IL179240A (en) Use of an antibody that binds to complement component c5 for the manufacture of medicaments to prolong the survival of an allograft and pharmaceutical packages and injection systems comprising said antibody
WO2010053777A3 (en) A mount having a push nut and a post
WO2006092741A3 (en) Treatment of inflammatory disorders with praziquantel
WO2005051307A3 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
WO2009148954A3 (en) Tpo mimetic peptide for preventing hematological disorder associated with cancer treatment
WO2005011605A3 (en) Combination therapies for multiple sclerosis
WO2005051293A3 (en) Methods and reagents for the treatment of inflammatory disorders
WO2009002790A3 (en) Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
GB0714008D0 (en) Game device, server device, and game system equipped with the devices

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase